ACE and heart failure: Thus, it is possible that TAK-272 could show more potent cardioprotective effect than other RAS inhibitors, an ACE inhibitor or an ARB, in clinical study, and TAK-272 become a first-line RAS inhibitor for the treatment of heart failure.